IMPEDIMED LIMITED — Capital/Financing Update 2009

Jun 29, 2009

30[th] June 2009

==> picture [110 x 104] intentionally omitted <==

----- Start of picture text ----- ASX : IPD----- End of picture text -----

ASX RELEASE – OFFER ACCEPTANCES

ImpediMed Limited advises that it has closed its renounceable 1-for-9 Entitlement Offer after receiving applications from eligible shareholders for approximately $1.2 million of new ordinary shares.

This represents a take-up of approximately 17 per cent under the Entitlement Offer announced on 28 May 2009. In accordance with Appendix 7A of the ASX Listing Rules, ImpediMed Limited advises that 9,022,153 shares were not taken up under the Entitlement Offer (“Shortfall Shares”).

As announced previously the Entitlement Offer was fully underwritten by Wilson HTM Corporate Finance Limited and the Shortfall Shares will be placed under that agreement.

Completion of the Entitlement Offer will result in the allotment of approximately 10,889,278 ImpediMed Limited ordinary shares.

ImpediMed Limited Chairman Mr Mel Bridges said “The company is very pleased with the support from Wilson HTM Corporate Finance who have facilitated the fully underwritten placement of $5.0 Million announced on 28[th] May 2009, and the Entitlement Offer of $7.0 Million. The $12 Million raised will allow the company to focus for the next 12 months on its business and on the achievement of the milestones it is targeting as outlined in the Offer Summary.”

Phil Auckland CFO & Company Secretary

About ImpediMed

ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed had the first medical device with an FDA clearance in the United States to aid health care professionals in the clinical assessment of secondary lymphoedema of the arm in female breast cancer patients. For more information, visit. www.impedimed.com.